GEN Exclusives

More »

GEN News Highlights

More »
May 23, 2007

Chembio and IDRI to Develop Tests for Leishmaniasis and Leprosy

  • Chembio Diagnostics and the Infectious Disease Research Institute (IDRI) entered into two R&D deals related to diagnostic tests for leishmaniasis and leprosy. Chembio will use its dual path immunoassay test platform, DPP™ and will incorporate IDRI’s antigens.

    Chembio reports that in preliminary studies during the first quarter of 2007, superior analytical sensitivity on certain well-characterized samples from patients with these diseases were observed.

    The organizations expect to complete prototype tests this year and then intend to seek commitments for procurement of these products for affected populations globally.

    IDRI receives funding from the NIH and the Bill and Melinda Gates Foundation for the development of vaccines and diagnostics for leishmaniasis and from the American Leprosy Mission for similar activities in leprosy.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »